Litigation

Recent Posts

$2.36B Glaxo Charge Covers Avandia, Paxil Litigation, Other Legal Costs
Posted on 15 Jul 2010 by Tom Moylan

LONDON - (Mealey's) GlaxoSmithKline PLC (GSK) on July 15 said it expects to take a $2.36 billion charge against earnings to settle several legal issues, including settling "the substantial majority" of Avandia product liability cases and... Read More

AstraZeneca Wins Patent Dispute Over Crestor
Posted on 30 Jun 2010 by LexisNexis Litigation Resource Community Staff

NEW YORK - (AP) AstraZeneca Plc said Tuesday it won a patent challenge brought against its blockbuster cholesterol drug Crestor by generic drug developers. The U.S. District Court in Delaware ruled that a key patent on the company's third best-selling... Read More

Glaxo Partner Pronova Settles Lovaza Patent Lawsuit
Posted on 31 Mar 2011 by LexisNexis Litigation Resource Community Staff

LONDON - (AP) GlaxoSmithKline PLC says U.S. patent litigation over the Omega-3 Lovaza drug has been settled, allowing generic drug company Apotex to eventually bring a competitor to market. Glaxo said Wednesday that Norway's Pronova BioPharma, which... Read More

Glaxo Takes $2.36 Billion Charge On Legal Costs
Posted on 15 Jul 2010 by LexisNexis Litigation Resource Community Staff

LONDON - (AP) Pharmaceutical company GlaxoSmithKline said Thursday it expects to take a $2.36 billion charge against second-quarter earnings for the costs of settling court cases over the antidepressant Paxil and diabetes drug Avandia. The company said... Read More